Mutations in ADAR1, IFIH1, and RNASEH2B Presenting As Spastic Paraplegia

Abstract

Background Hereditary spastic paraplegia is a neurodegenerative phenotype characterized by a progressive loss of corticospinal motor tract function. In a majority of affected individuals the pathogenesis remains undetermined.

Methods We identified a series of patients with a phenotype of nonsyndromic spastic paraplegia in whom no diagnosis had been reached before exome sequencing. We measured the expression of interferon stimulated genes (ISGs) in peripheral blood from these patients.

Results Five patients from four families with previously unexplained spastic paraplegia were identified with mutations in either ADAR1 (one patient), IFIH1 (one patient), or RNASEH2B (three patients from two families). All patients were developmentally normal before the onset of features beginning in the second year of life. All patients remain of normal intellect. Four patients demonstrated normal neuroimaging, while a single patient had features of nonspecific dysmyelination. The patients with ADAR1 and IFIH1-related disease showed a robust interferon signature. The patients with mutations in RNASEH2B demonstrated no (two patients) or a minimal (one patient) upregulation of ISGs compared with controls.

Conclusions Mutations in ADAR1, IFIH1, and RNASEH2B can cause a phenotype of spastic paraplegia with normal neuroimaging, or in association with nonspecific dysmyelination. Although the presence of an interferon signature can be helpful in interpreting the significance of gene variants in this context, patients with pathogenic mutations in RNASEH2B may demonstrate no upregulation of ISGs in peripheral blood. However, it remains possible that type I interferons act as a neurotoxin in the context of all genotypes.

Keywords

Aicardi–Goutières syndrome - spastic paraparesis - RNASEH2B - ADAR1 - IFIH1 - type I interferon - type I interferonopathy

• References

• 1 Blackstone C. Cellular pathways of hereditary spastic paraplegia. Annu Rev Neurosci 2012; 35: 25-47
• 2 Novarino G, Fenstermaker AG, Zaki MS , et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014; 343 (6170) 506-511
• 3 Crow YJ, Hayward BE, Parmar R , et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet 2006; 38 (8) 917-920
• 4 Crow YJ, Leitch A, Hayward BE , et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat Genet 2006; 38 (8) 910-916
• 5 Rice GI, Bond J, Asipu A , et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009; 41 (7) 829-832
• 6 Rice GI, Kasher PR, Forte GM , et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet 2012; 44 (11) 1243-1248
• 7 Rice GI, del Toro Duany Y, Jenkinson EM , et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014; 46 (5) 503-509
• 8 Ramesh V, Bernardi B, Stafa A , et al. Intracerebral large artery disease in Aicardi-Goutières syndrome implicates SAMHD1 in vascular homeostasis. Dev Med Child Neurol 2010; 52 (8) 725-732
• 9 Dale RC, Gornall H, Singh-Grewal D, Alcausin M, Rice GI, Crow YJ. Familial Aicardi-Goutières syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures. Am J Med Genet A 2010; 152A (4) 938-942
• 10 Vogt J, Agrawal S, Ibrahim Z , et al. Striking intrafamilial phenotypic variability in Aicardi-Goutières syndrome associated with the recurrent Asian founder mutation in RNASEH2C. Am J Med Genet A 2013; 161A (2) 338-342
• 11 Livingston JH, Lin JP, Dale RC , et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet 2014; 51 (2) 76-82
• 12 Rice GI, Forte GM, Szynkiewicz M , et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol 2013; 12 (12) 1159-1169
• 13 Akwa Y, Hassett DE, Eloranta ML , et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 1998; 161 (9) 5016-5026
• 14 Campbell IL, Krucker T, Steffensen S , et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res 1999; 835 (1) 46-61
• 15 Fritz-French C, Tyor W. Interferon-α (IFNα) neurotoxicity. Cytokine Growth Factor Rev 2012; 23 (1-2) 7-14
• 16 Rice G, Patrick T, Parmar R , et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007; 81 (4) 713-725
• 17 Uggetti C, La Piana R, Orcesi S, Egitto MG, Crow YJ, Fazzi E. Aicardi-Goutieres syndrome: neuroradiologic findings and follow-up. AJNR Am J Neuroradiol 2009; 30 (10) 1971-1976
• 18 Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI. Therapies in Aicardi-Goutières syndrome. Clin Exp Immunol 2014; 175 (1) 1-8